FDA Clearance

When the Growth Round Comes After the Hardest Proof

Bridge to Life raised $110 million in August, but the number is less interesting than the sequencing. The company had already received FDA De Novo clearance for its VitaSmart liver-perfusion system in January. By the time the Series C and debt financing closed, the company was raising to expand commercial rollout and build its next products, not to find out whether its core system could clear its largest regulatory hurdle. Bridge to Life’s financing announcement makes that unusually explicit.